Gladstone Institutional Advisory’s aTyr Pharma ATYR Stock Holding History

Gladstone Institutional Advisory’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.74K	Hold	11,300	–	–	﹤0.01%	891
2026 Q1	$8.81K	Hold	11,300	–	–	﹤0.01%	828
2025 Q4	$8.85K	Sell	11,300 -2,000	-15%	-$1.64K	﹤0.01%	788
2025 Q3	$9.6K	Buy	13,300 +2,500	+23%	+$11.3K	﹤0.01%	783
2025 Q2	$54.8K	Buy	+10,800	New	+$42.5K	﹤0.01%	747

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gladstone Institutional Advisory's ATYR Position: Q2 2026 in Review

Gladstone Institutional Advisory held its aTyr Pharma (ATYR) position steady in Q2 2026 at 11,300 shares worth $6.74K. The position accounts for ﹤0.01% of the portfolio, ranked #891.

Gladstone Institutional Advisory first reported a position in ATYR in Q2 2025 and has held it in 5 quarters since. The position peaked at $54.8K in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Gladstone Institutional Advisory held 11,300 shares of aTyr Pharma worth $6.74K as of Q2 2026.
Gladstone Institutional Advisory left its aTyr Pharma share count unchanged in Q2 2026.
aTyr Pharma made up ﹤0.01% of Gladstone Institutional Advisory's portfolio in Q2 2026, its #891 holding.
Gladstone Institutional Advisory first reported a position in aTyr Pharma in Q2 2025 and has held it in 5 quarters since.
Gladstone Institutional Advisory's aTyr Pharma position peaked at $54.8K in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.